Decentralisation by design: Bringing the trial closer without adding complexity

As clinical trials become more complex, sponsors face growing pressure to reach more representative patient populations while reducing participation burden and keeping studies moving without adding strain to sites.

In the third episode of our PSCS leadership discussion series, developed in partnership with IQVIA, Sinead Callinan, Head of Patient Centred Delivery at IQVIA, speaks with pharmaphorum’s Deep Dive Editor, Eloise McLennan, about how decentralised and hybrid trial design can make access more practical and operational.

Together, they explore how early patient insight, site readiness, protocol requirements, visit schedules, remote services, digital engagement, and country-specific considerations can be brought together to determine where decentralisation adds value and where it may introduce risk if planned too late.

The discussion also considers the role of country-specific requirements and why decentralised solutions work best when they are designed into a trial from the outset, rather than added later as a rescue tactic.

Watch the full conversation to explore how sponsors can build more accessible, resilient trials around the realities of patients and sites.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialisation of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analysing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.